
Lisa Coussens

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8324817/publications.pdf Version: 2024-02-01



LIGA COLISSENS

#	Article	IF	CITATIONS
1	Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment. Cancer Cell, 2012, 21, 309-322.	16.8	3,578
2	Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature Medicine, 2018, 24, 541-550.	30.7	3,421
3	Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science, 2018, 359, 97-103.	12.6	3,126
4	Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discovery, 2011, 1, 54-67.	9.4	1,486
5	Macrophages and Therapeutic Resistance in Cancer. Cancer Cell, 2015, 27, 462-472.	16.8	1,130
6	Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?. Science, 2013, 339, 286-291.	12.6	943
7	Macrophages and Metabolism in the Tumor Microenvironment. Cell Metabolism, 2019, 30, 36-50.	16.2	933
8	Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells. Cancer Cell, 2014, 26, 623-637.	16.8	751
9	The Basis of Oncoimmunology. Cell, 2016, 164, 1233-1247.	28.9	671
10	Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets. Cancer Cell, 2019, 35, 588-602.e10.	16.8	636
11	Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity, 2018, 49, 178-193.e7.	14.3	502
12	Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis. Cell Reports, 2017, 19, 203-217.	6.4	454
13	Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer. Cancer Discovery, 2016, 6, 270-285.	9.4	408
14	Leukocyte composition of human breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2796-2801.	7.1	393
15	Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nature Cell Biology, 2019, 21, 190-202.	10.3	384
16	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell, 2020, 181, 236-249.	28.9	334
17	CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 ⁺ T cells. Oncolmmunology, 2013, 2, e26968.	4.6	311
18	Early detection of cancer. Science, 2022, 375, eaay9040.	12.6	291

#	Article	IF	CITATIONS
19	TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. Cancer Cell, 2018, 33, 60-74.e6.	16.8	270
20	Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Science Advances, 2018, 4, eaat7828.	10.3	203
21	TH2-Polarized CD4+ T Cells and Macrophages Limit Efficacy of Radiotherapy. Cancer Immunology Research, 2015, 3, 518-525.	3.4	197
22	Immune Escape in Breast Cancer During <i>In Situ</i> to Invasive Carcinoma Transition. Cancer Discovery, 2017, 7, 1098-1115.	9.4	185
23	Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression. Nature Materials, 2021, 20, 548-559.	27.5	125
24	The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Nature Communications, 2019, 10, 4682.	12.8	123
25	Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 165-174.	3.8	123
26	A Listeria Vaccine and Depletion of T-Regulatory Cells Activate Immunity Against Early Stage Pancreatic Intraepithelial Neoplasms and Prolong Survival of Mice. Gastroenterology, 2014, 146, 1784-1794.e6.	1.3	118
27	Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy. Cancer Cell, 2018, 34, 561-578.e6.	16.8	113
28	MCMICRO: a scalable, modular image-processing pipeline for multiplexed tissue imaging. Nature Methods, 2022, 19, 311-315.	19.0	102
29	Immune Response to Cancer Therapy: Mounting an Effective Antitumor Response and Mechanisms of Resistance. Trends in Cancer, 2015, 1, 66-75.	7.4	101
30	Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Clinical Cancer Research, 2021, 27, 4574-4586.	7.0	82
31	Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Cancer Discovery, 2021, 11, 2014-2031.	9.4	79
32	Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 3578-3588.	7.0	76
33	Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Clinical Cancer Research, 2021, 27, 1069-1081.	7.0	75
34	Clinical Response of Live-Attenuated, <i>Listeria monocytogenes</i> Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma. Clinical Cancer Research, 2019, 25, 5787-5798.	7.0	72
35	Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. Cancer Immunology Research, 2019, 7, 1025-1035.	3.4	70
36	Lymphatic Vessels, Inflammation, and Immunity in Skin Cancer. Cancer Discovery, 2016, 6, 22-35.	9.4	69

#	Article	IF	CITATIONS
37	Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. Annals of Oncology, 2021, 32, 600-608.	1.2	69
38	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131.		64
39	B cells and their mediators as targets for therapy in solid tumors. Experimental Cell Research, 2013, 319, 1644-1649.	2.6	63
40	Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer. Cancer Discovery, 2020, 10, 1489-1499.	9.4	60
41	Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. Nature Reviews Drug Discovery, 2022, 21, 440-462.	46.4	58
42	Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer. Clinical Cancer Research, 2019, 25, 5351-5363.	7.0	57
43	High-dimensional multiplexed immunohistochemical characterization of immune contexture in human cancers. Methods in Enzymology, 2020, 635, 1-20.	1.0	57
44	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncolmmunology, 2016, 5, e1136044.	4.6	55
45	MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment. Nature Communications, 2016, 7, 13597.	12.8	54
46	Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. , 2018, 6, 118.		43
47	Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. , 2018, 6, 98.		43
48	MITI minimum information guidelines for highly multiplexed tissue images. Nature Methods, 2022, 19, 262-267.	19.0	37
49	Senescence and cancer: An evolving inflammatory paradox. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 14-22.	7.4	35
50	Duality of the Immune Response in Cancer: Lessons Learned from Skin. Journal of Investigative Dermatology, 2014, 134, E23-E28.	0.7	23
51	Single-cell spatial architectures associated with clinical outcome in head and neck squamous cell carcinoma. Npj Precision Oncology, 2022, 6, 10.	5.4	23
52	Hepatic thrombopoietin gene silencing reduces platelet count and breast cancer progression in transgenic MMTV-PyMT mice. Blood Advances, 2019, 3, 3080-3091.	5.2	22
53	An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer. Cell Reports Medicine, 2022, 3, 100525.	6.5	22
54	Trim32 Deficiency Enhances Th2 Immunity and Predisposes to Features of Atopic Dermatitis. Journal of Investigative Dermatology, 2017, 137, 359-366.	0.7	21

#	Article	IF	CITATIONS
55	Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV+ Cancers. Cancer Immunology Research, 2020, 8, 131-145.	3.4	21
56	Sustained Endothelial Expression of HoxA5 In Vivo Impairs Pathological Angiogenesis And Tumor Progression. PLoS ONE, 2015, 10, e0121720.	2.5	20
57	Tumor immune microenvironment characteristics of papillary thyroid carcinoma are associated with histopathological aggressiveness and BRAF mutation status. Head and Neck, 2019, 41, 2636-2646.	2.0	20
58	Innate αβ T Cells Mediate Antitumor Immunity by Orchestrating Immunogenic Macrophage Programming. Cancer Discovery, 2019, 9, 1288-1305.	9.4	19
59	High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer. Breast Cancer Research, 2021, 23, 40.	5.0	18
60	Robust Cell Detection and Segmentation for Image Cytometry Reveal Th17 Cell Heterogeneity. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2019, 95, 389-398.	1.5	17
61	Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC. Journal of Thoracic Oncology, 2021, 16, 1211-1223.	1.1	17
62	A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs. Nature Biotechnology, 2022, 40, 1823-1833.	17.5	17
63	Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study. Clinical Cancer Research, 2022, 28, 903-914.	7.0	14
64	Alk5 inhibition increases delivery of macromolecular and protein-bound contrast agents to tumors. JCI Insight, 2016, 1, .	5.0	13
65	Spatial Profiles of Intratumoral PD-1+ Helper T Cells Predict Prognosis in Head and Neck Squamous Cell Carcinoma. Frontiers in Immunology, 2021, 12, 769534.	4.8	12
66	Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies. Npj Precision Oncology, 2021, 5, 92.	5.4	11
67	Manipulating MicroRNAs to Regulate Macrophage Polarization in Gliomas. Journal of the National Cancer Institute, 2014, 106, dju230-dju230.	6.3	6
68	Deciphering the Immune Complexity in Esophageal Adenocarcinoma and Pre-Cancerous Lesions With Sequential Multiplex Immunohistochemistry and Sparse Subspace Clustering Approach. Frontiers in Immunology, 2022, 13, .	4.8	6
69	Surgical Procedures and Methodology for a Preclinical Murine Model of De Novo Mammary Cancer Metastasis. Journal of Visualized Experiments, 2017, , .	0.3	5
70	Redirecting tumor macrophage activity to fight cancer: Make room for the next era of anti-cancer drugs. Cancer Cell, 2021, 39, 1300-1302.	16.8	3
71	Zena Werb 1945–2020. Nature Cancer, 2020, 1, 753-754.	13.2	1
72	Abstract CT005: T cell inflammation in the tumor microenvironment after agonist CD40 antibody:		0

² Clinical and translational results of a neoadjuvant clinical trial., 2021, ,.

#	Article	IF	CITATIONS
73	Abstract PO-095: A cancer cell-intrinsic GOT2-PPARÎ $^{\prime}$ axis suppresses antitumor immunity. , 2021, , .		Ο
74	T-cell Dysfunction upon Expression of MYC with Altered Phosphorylation at Threonine 58 and Serine 62. Molecular Cancer Research, 2022, 20, 1151-1165.	3.4	0
75	Novel Therapeutics Modulate Cardiac Leukocyte Populations Following Myocardial Infarction. FASEB Journal, 2022, 36, .	0.5	0